Effects of cyclooxygenase-2 non-selective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells

Diseases of the Esophagus

Volumn 22, Issue 1, 2009, Pages 21-31

  Li, P ^a   Zhang, S T ^a   Yu, Z L ^a   Wu, Y D ^a   Liu, X ^a   Xu, C M ^b   Cho, C H ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Cyclooxygenase 2; Esophageal squamous cell carcinoma; Growth inhibition

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NIMESULIDE; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DINOPROSTONE; ESOPHAGEAL NEOPLASMS; HUMANS; IN SITU NICK-END LABELING; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES;

EID: 58749107729     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00836.x     Document Type: Article

References (32)

1. Stewart B W, Kleihues P. World Cancer Report 2003 IARC Press, Lyon, France.
2. Gamliel Z. Incidence, epidemiology and etiology of esophageal cancer. Chest Surg Clin N Am 2000; 10: 441-50.
3. Stathopoulos G P, Tsiaras N. Epidemiology and pathogenesis of esophageal cancer: Management and its controversial results. Oncol Rep 2003; 10: 449-54.
4. Blot W J, McLaughlin J K. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26: 2-8.
5. Richter M, Weiss M, Weinberger I, Furstenberger G., Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001; 22: 17-25.
6. Subbaramaiah K, Telang N, Ramonetti J T, Araki R, Devito B, Weksler B B (eds). Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996; 56: 4424-9.
7. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-40.
8. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY (eds). Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 519-25.
9. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A (eds). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001.
10. Yu H P, Shi L Y, Lu W H, Su Y H, Li Y Y, Xu S Q (eds). Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol 2004; 19: 638-42.
11. Kase S, Osaki M, Honjo S, Hashimoto K, Adachi H, Tsujitani S (eds). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma. Pathobiology 2004; 71: 84-92.
12. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y (eds). Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6: 1229-38.
13. Kawabe A, Shimada Y, Uchida S, Maeda M, Sato F, Itami A (eds). Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and P53 expression. Oncology 2002; 62: 46-54.
14. Corley D A, Kerlikowske K, Verma R, Buffler P. Protective association of asprine/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
15. Danial N N, Korsmeyer S J. Cell death: Critical control points. Cell 2004; 116: 205-19.
16. Green D R, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-9.
17. Findley H W, Gu L, Yeager A M, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997; 89: 2986-93.
18. Salomons G S, Brady H J, Verwijs-Janssen M, Van Den Berg J D, Hart A A, Van Den Berg H (eds). The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 1997; 71: 959-65.
19. Li S D, Zhang L R, Luo X, Ao P. Cytogenetic studies on 3 esophageal cancer cell lines. Zhonghua Zhong Liu Za Zhi 1987; 9: 90-4.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 5563.
21. Tang X Q, Bi H, Feng J Q, Cao J G. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005; 26: 1009-16.
22. Funkhouser E M, Sharp G B. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995; 76: 1116-9.
23. Langman M J, Cheng K K, Gilman E A, Lancashire R J. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. Br Med J 2000; 320: 1642-46.
24. Wilson K T, Fu S, Ramanujam K S, Meltzer S J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-34.
25. Li M, Lotan R, Levin B, Tahara E, Lippman S M, Xu X C (eds). Aspirin induction of apoptosis in esophageal cancer. A potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000; 9: 545-9.
26. Aggarwal S, Taneja N, Lin L, Orringer M B, Rehemtulla A, Beer D G (eds). Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independence of COX-2 expression. Neoplasia 2000; 2: 346-56.
27. Maaser K, Daubler P, Barthel B, Heine B, von Lampe B, Stein H (eds). Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer 2003; 88: 1217-22.
28. Biramijamal F, Allamch A, Mirbod P, Groene H J, Koomagi R, Hollstein M (eds). Unusual profile and high prevalence of P53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res 2001; 61: 3119-23.
29. Bardou M, Barkun A N, Ghosn J, Hudson M, Rahme E. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2004; 2: 880-7.
30. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem; 91: 223-31.
31. Scorrano L, Korsmeyer S J. Mechanism of cytochrome c release by apoptotic BCL-2 family members. Biochem Biophys Res Commun 2003; 304: 437-44.
32. 2 in human colon cancer cells. Cancer Res 1998; 58: 362-6.